FY2024 EPS Estimates for Humacyte Cut by HC Wainwright

Humacyte, Inc. (NASDAQ:HUMA) – Equities research analysts at HC Wainwright reduced their FY2024 earnings estimates for shares of Humacyte in a report released on Wednesday, November 13th. HC Wainwright analyst V. Bernardino now forecasts that the company will post earnings of ($1.36) per share for the year, down from their previous forecast of ($1.28). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Humacyte’s FY2025 earnings at ($0.77) EPS.

A number of other research analysts have also weighed in on the company. Benchmark reissued a “buy” rating and set a $15.00 target price on shares of Humacyte in a report on Thursday, October 10th. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. BTIG Research reaffirmed a “buy” rating and set a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 price target on shares of Humacyte in a report on Friday, September 20th. Finally, TD Cowen restated a “buy” rating and set a $10.00 price objective on shares of Humacyte in a report on Friday, October 18th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $11.00.

Humacyte Stock Performance

Shares of HUMA stock opened at $4.84 on Friday. The company has a fifty day moving average price of $5.42 and a two-hundred day moving average price of $6.17. Humacyte has a one year low of $2.35 and a one year high of $9.97. The stock has a market cap of $577.06 million, a P/E ratio of -3.61 and a beta of 1.47. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 5.41.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in HUMA. nVerses Capital LLC bought a new stake in shares of Humacyte during the 2nd quarter valued at about $28,000. Concurrent Investment Advisors LLC bought a new position in shares of Humacyte during the 3rd quarter worth approximately $75,000. Principal Financial Group Inc. acquired a new stake in shares of Humacyte during the 2nd quarter worth approximately $83,000. FORA Capital LLC bought a new stake in shares of Humacyte in the 3rd quarter valued at $96,000. Finally, Profund Advisors LLC bought a new position in Humacyte during the second quarter worth $97,000. 44.71% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Laura E. Niklason sold 157,704 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $5.42, for a total value of $854,755.68. Following the sale, the chief executive officer now directly owns 3,519,558 shares in the company, valued at $19,076,004.36. This represents a 4.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Brady W. Dougan sold 352,112 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $6.35, for a total transaction of $2,235,911.20. Following the transaction, the director now owns 3,677,262 shares of the company’s stock, valued at approximately $23,350,613.70. The trade was a 8.74 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,084,153 shares of company stock valued at $6,869,996 in the last ninety days. 11.20% of the stock is currently owned by insiders.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.